IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-50199-y.html
   My bibliography  Save this article

GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease

Author

Listed:
  • Heng-Chih Pan

    (College of Medicine, National Taiwan University
    Chang Gung University College of Medicine
    Keelung Chang Gung Memorial Hospital
    Keelung Chang Gung Memorial Hospital)

  • Jui-Yi Chen

    (Chi Mei Medical Center
    Chia Nan University of Pharmacy and Science)

  • Hsing-Yu Chen

    (College of Medicine, Chang Gung University
    Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital
    College of Medicine, Chang Gung University)

  • Fang-Yu Yeh

    (National Taiwan University Hospital)

  • Chiao-Yin Sun

    (Keelung Chang Gung Memorial Hospital
    Linkou Chang Gung Memorial Hospital)

  • Thomas Tao-Min Huang

    (National Taiwan University Hospital
    and CAKS (Taiwan Consortium for Acute Kidney Injury and Renal Diseases))

  • Vin-Cent Wu

    (National Taiwan University Hospital
    and CAKS (Taiwan Consortium for Acute Kidney Injury and Renal Diseases))

Abstract

Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD). Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients. The most common causes of AKI are sepsis (55.2%) and cardiorenal syndrome (34.2%). After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73). External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes. These results emphasize the potential of GLP-1 RAs in individualized treatment for this population.

Suggested Citation

  • Heng-Chih Pan & Jui-Yi Chen & Hsing-Yu Chen & Fang-Yu Yeh & Chiao-Yin Sun & Thomas Tao-Min Huang & Vin-Cent Wu, 2024. "GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease," Nature Communications, Nature, vol. 15(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-50199-y
    DOI: 10.1038/s41467-024-50199-y
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-50199-y
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-50199-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-50199-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.